The aim of the present study was to investigate the efficacy and tolerability of acupuncture (AC), Tanacetum (TAN) or combined treatment on quality of life in women with chronic migraine (CM).
Methods
A total of 69 women volunteers were randomly divided into 3 groups: AC, acupuncture administered in 20 sessions over 10 weeks (n=22); TAN, at 150 mg/day (n=23); and AC+TAN (n=23). The primary outcome was Short-Form 36 (SF-36) quality of life assessment score. Secondary outcomes included the Migraine Disability Assessment (MIDAS) and visual analogue scale (VAS) score experienced after randomisation.
Results
AC+TAN was statistically significantly more effective than AC or TAN alone in overall health-related quality of life (SF-36; p<0.05), on MIDAS score (−35.1 (10.6) AC vs −24.8 (11.7) TAN vs −42.5 (9.8) AC+TAN; p<0.05) and in reducing the mean score of pain on VAS (−5.6 (2.4) AC vs −3.7 (2.1) TAN vs −6.4 (3.1) AC+TAN; p<0.05).
Conclusions
The present work shows an improvement of the quality of life and better analgesic effect of acupuncture combined with TAN treatment on migraine pain in women when compared with acupuncture or TAN alone.
JenaS, WittCM, BrinkhausB, Acupuncture in patients with headache. Cephalalgia2008;28:969.
2.
MathewN.The prophylactic treatment of chronic daily headache. Headache2006;46:1552–64.
3.
SilbersteinD.Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology2000;55:754–62.
4.
AllaisG, De LorenzoC, QuiricoPE, Acupuncture in the prophylactic treatment of migraine without aura: a comparison with flunarizine. Headache2002;42:855–61.
5.
Headache Classification Subcommittee of the International Headache Society. The International classification of headache disorders: 2nd edition. Cephalalgia2004;24:9–160.
6.
OlesenJ, BousserMG, DienerHC, New appendix criteria open for a broader concept of chronic migraine. Cephalalgia2006;26:742–6.
7.
OlesenJ, Tfelt-HansenP, RamadanN, The headaches.Philadelphia, PA: Lippincott Williams & Wilkins, 2005, 28–56.
8.
LuSR, FuhJL, ChenWT, Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia2001;21:980–6.
9.
BigalME, SerranoD, ReedM, Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology2008;71:559–66.
10.
NatoliJ, ManackA, DeanB, Global prevalence of chronic migraine: a systematic review. Cephalalgia2010;30:599–609.
11.
DienerHC, LimmrothV.Medication-overuse headache: a worldwide problem. Lancet Neurol2004;3:475–83.
12.
LiptonRB, BigalME, DiamondM, Migraine prevalence, disease burden, and the need for preventive therapy. Neurology2007;68:343–9.
13.
JuangKD, WangSJ, FuhJL, Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache2000;40:818–23.
14.
DodickDW. Clinical practice. Chronic daily headache. N Engl J Med2006;354:158–65.
15.
MunakataJ, HazardE, SerranoD, Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache2009;49:498–508.
16.
GaulC, EismannR, SchmidtT, Use of complementary and alternative medicine in patients suffering from primary headache disorders. Cephalalgia2009;29:1069–78.
17.
WittCM, ReinholdT, JenaS, Cost-effectiveness of acupuncture treatment in patients with headache. Cephalalgia2008;28:334–45.
CheongY, NardoLG, RutherfordT, Acupuncture and herbal medicine in in vitro fertilisation: a review of the evidence for clinical practice. Hum Fertil2010;13:3–12.
20.
Yeh-chingL, JiahuiL, Lay-chengL, Traditional Chinese herbal medicine in the supportive management of patients with chronic cytopaenic marrow diseases-a phase I/II clinical study. Complement Ther Clin Pract2001;17:152–6.
21.
ZhuX, ProctorM, BensoussanA, Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev2008;16:CD005288.
22.
PilkingtonK, RampesH, RichardsonJ.Complementary medicine for depression. Expert Rev Neurother2006;6:1741–51.
23.
PeatfieldR.Drugs and the treatment of migraine. Trends Pharmacol Sci1988;9:141–5.
24.
MagniP, RuscicaM, DozioE, Parthenolide inhibits the LPS-induced secretion of IL-6 and TNF-α and NF-κB nuclear translocation in BV-2 Microglia. Phytother Res2012;23. doi: 10.1002/ptr.3732.
25.
MurdochJ.Feverfew for migraine prophylaxis. Can J Hospital Pharm1989;42:209–10.
26.
De WeerdtCJ, BootsmaHPR, HendriksH.Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine1996;3:225–30.
27.
BanthorpeDV, BrownGD, JanesJF, Parthenolide and other volatilies in the flowerheads of Tenacetum parthenium (L.) Schultz Bip. Flavour Fragr1990;5:183–5.
28.
AwangDVC. Feverfew fever. A headache for consumer. Herbal Gram1993;29:34–6.
29.
HwangD, FischerNH, JangBC, Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun1996;226:810–18.
30.
KangBY, ChungSW, KimTS. Inhibition of interleukin-12 production in lipopolysaccharide-activated mouse macrophages by parthenolide, a predominant sesquiterpene lactone in Tanacetum parthenium: involvement of nuclear factor-kappa B. Immunol Lett2001;77:159–63.
PalevitchD, EaronG, CarassoR.Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytotherapy Res1997;11:508–11.
33.
MurphyJJ, HeptinstallS, MitchellJRA. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet, 1988:189–92.
34.
VoglerBK, PittlerWH, ErnstE.Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia1998;18:704–8.
35.
SchiapparelliP, AllaisG, RolandoS, Acupuncture in primary headache treatment. Neurol Sci2011;32:S15–18.
36.
MacPhersonH, WhiteA, CummingsM, Standards for reporting interventions in controlled trials of acupuncture: the STRICTA recommendations. J Altern Complement Med2002;8:85–9.
37.
ErnstE, PittlerMH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutr2000;3:509–14.
38.
SilbersteinSD. Migraine pathophysiology and its clinical implications. Cephalalgia2004;24:2–7.
39.
FanciullacciM, De CesarisF.Preventing chronicity of migraine. J Headache Pain2005;6:331–3.
40.
ZijlstraFJ, van den Berg-de LangeI, HuygenFJ, Anti-inflammatory actions of acupuncture. Mediators Inflamm2003;12:59–69.
41.
HumphreyPP, FeniukW, PerrenMJ, Serotonin and migraine. Ann N Y Acad Sci1990;600:587–600.
42.
HumphreyPP. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol1991;238:S38–44.
43.
LanceJW. 5-Hydroxytryptamine and its role in migraine. Eur Neurol1991;31: 279–81.
44.
FeniukW, HumphreyPP, PerrenMJ, Rationale for the use of 5-HT1-like agonists in the treatment of migraine. J Neurol1991;238:S57–61.
45.
JohnGW, GoadsbyPJ. Triptan signal transduction. In: OlesenJ, Tfelt-HansenP, WelchKMA. eds. The headaches. Chapp. 21-. 3rd edn. Pennsylvania: Lippincott Williams & Wilkins, 2006:203–11.
46.
MassiouH, BousserMG. Prophylactic drug treatment of migraine. Rev Neurol (Paris)2005;161:681–4.
47.
DienerHC, LimmrothV.Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs2001;10:1831–45.
BarsbyRW, SalanU, KnightDW, Feverfew and vascular smooth muscle: extracts from fresh and dried plants show opposing pharmacological profiles, dependent upon sesquiterpene lactone content. Planta Med1993;59:20–5.
50.
BéjarE.Parthenolide inhibits the contractile responses of rat stomach fundus to fenfluramine and dextroamphetamine but not serotonin. J Ethnopharmacol1996;50:1–12.
51.
MittraS, DattaA, SinghSK, 5-Hydroxytryptamine-inhibiting property of feverfew: role of parthenolide content. Acta Pharmacol Sin2000;21:1106–14.
52.
WeberJT, O'ConnorMF, HayatakaK, Activity of parthenolide at 5HT2A receptors. J Nat Prod1997;60:651–3.
53.
ShrivastavaR, PechadreJC, JohnGW. Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. Clin Drug Investig2006;26:287–96.
54.
MacedoA, BañosJE, FarréM.Placebo response in the prophylaxis of migraine: a meta-analysis. Eur J Pain2008;12:68–75.
55.
HungPH, FuhJL, WangSJ. Validity, reliability and application of the taiwan version of the migraine disability assessment questionnaire. J Formos Med Assoc2006;105:563–8.
56.
MitchellN, HewittCE, JayakodyS, Randomised controlled trial of food elimination diet based on IgG antibodies for the prevention of migraine like headaches. Nutr J2011;11:10:85.
57.
MolsbergerAL. Designing an acupuncture study: the nationwide, randomized, controlled, German acupuncture trials on migraine and tension-type headache. J Altern Complement Med2006;12:237–45.
